Xia, K. and Peng, Y. and Jiang, Z. and Wang, Y. and Shi, W. and Chen, M. and Li, G. and Zhao, Z. and Jian, D.
doi:10.1080/09546634.2026.2665538
Abstract
Oral doxycycline (DOX) is a first-line systemic therapy for rosacea; however, persistent vascular features, such as fixed erythema and flushing, and neurosensory symptoms, such as burning, may respond incompletely to DOX alone. This study aimed to evaluate whether adding microneedling to oral DOX improves clinical outcomes in patients with rosacea.